2P5A0261 kvadrat rbg
![](https://mb.cision.com/Public/14910/2983237/b70034e92b91c23f_800x800ar.jpg)
Photographer: Alex Giacomini, Lilla produktionsbolaget
Anders Rylander, vd BiovicaPhotographer: Alex Giacomini, Lilla produktionsbolaget
Anders Rylander, vd BiovicaBiovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality. Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum™ is CE-labeled and MPA-registered.